Skip to menu Skip to content Skip to footer
Professor

Roslyn Francis

Email: 

Overview

Availability

Professor Roslyn Francis is:
Available for supervision

Works

Search Professor Roslyn Francis’s works on UQ eSpace

93 works between 2006 and 2025

1 - 20 of 93 works

2025

Journal Article

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

2025

Journal Article

Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET/CT

Molin, Kaylee, Barry, Nathaniel, Gill, Suki, Hassan, Ghulam Mubashar, Francis, Roslyn J., Ong, Jeremy S. L., Ebert, Martin A. and Kendrick, Jake (2025). Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET/CT. Physical and Engineering Sciences in Medicine, 1-13. doi: 10.1007/s13246-024-01516-8

Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET/CT

2025

Journal Article

Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine

Thunold, Solfrid, Hernes, Eivor, Farooqi, Saima, Öjlert, Åsa Kristina, Francis, Roslyn J., Nowak, Anna K., Szejniuk, Weronika Maria, Nielsen, Søren Steen, Cedres, Susana, Perdigo, Marc Simo, Sørensen, Jens Benn, Meltzer, Carin, Mikalsen, Lars Tore Gyland, Helland, Åslaug, Malinen, Eirik and Haakensen, Vilde Drageset (2025). Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. European Journal of Nuclear Medicine and Molecular Imaging, 52 (2), 693-707. doi: 10.1007/s00259-024-06853-0

Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine

2024

Conference Publication

Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma

Lewis, Katharine L., Giri, Pratyush, Marconi, Tamara, Blombery, Piers, Keane, Colm, Sungala, Nagendra Prasad, Cochrane, Tara, Ma, Chun Kei Kris, Vanguru, Vinay, Manos, Kate, Francis, Roslyn, Walia, Mannu, Carlson, Julia, Butcher, Belinda E. and Cheah, Chan Y. (2024). Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-204317

Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma

2024

Conference Publication

Multi-site, Prospective Trial Evaluating FET-PET In Glioblastoma (FIG) Study (TROG 18.06): Preliminary Results Of Central Nuclear Medicine Review Of FET-PET Biologic Target Volume Delineation For Radiation Planning

Koh, Eng-Siew, Francis, Roslyn, Lee, SzeTing, Lau, Eddie, Thomas, Elizabeth, Whitehead, Angela, Cook, Olivia, Dykyj, Rachael, Moore, Alisha, Rossi, Alana, Thomas, Paul, Pattison, David, Akhurst, Tim, Alipour, Ramin, Hsiao, Edward, Schembri, Geoffrey, Lin, Peter, Yap, June, Ly, Tam, Kirkwood, Ian, Vallat, Wilson, Krishna, Dayanethee Krishna, Khan, Shahroz Khan, Ngai, Stanley Ngai, Yu, Chris, Beuzeville, Scott, Yeow, Tow Chan, Barry, Nathaniel, Ebert, Martin ... Scott, Andrew M. (2024). Multi-site, Prospective Trial Evaluating FET-PET In Glioblastoma (FIG) Study (TROG 18.06): Preliminary Results Of Central Nuclear Medicine Review Of FET-PET Biologic Target Volume Delineation For Radiation Planning. 2024 Society for Neuro-Oncology’s 29th Annual Meeting and Education Day, Houston, TX United States, 21-24 November 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/neuonc/noae165.0806

Multi-site, Prospective Trial Evaluating FET-PET In Glioblastoma (FIG) Study (TROG 18.06): Preliminary Results Of Central Nuclear Medicine Review Of FET-PET Biologic Target Volume Delineation For Radiation Planning

2024

Journal Article

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

Azad, Arun A, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, Hofman, Michael S, Akhurst, T, Alipour, R, Au, L, Banks, P ... Ratnayake, L (2024). Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. The Lancet Oncology, 25 (10), 1267-1276. doi: 10.1016/s1470-2045(24)00440-6

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

2024

Journal Article

Assessing the heterogeneity of response of [68Ga] Ga-PSMA-11 PET/CT lesions in patients with biochemical recurrence of prostate cancer

Dell'Oro, Mikaela, Huff, Daniel T., Lokre, Ojaswita, Kendrick, Jake, Munian Govindan, Rajkumar, Ong, Jeremy S. L., Ebert, Martin A., Perk, Timothy G. and Francis, Roslyn J. (2024). Assessing the heterogeneity of response of [68Ga] Ga-PSMA-11 PET/CT lesions in patients with biochemical recurrence of prostate cancer. Clinical Genitourinary Cancer, 22 (5) 102155, 102155. doi: 10.1016/j.clgc.2024.102155

Assessing the heterogeneity of response of [68Ga] Ga-PSMA-11 PET/CT lesions in patients with biochemical recurrence of prostate cancer

2024

Journal Article

Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT

Parry, R., Wright, K., Bellinge, J. W., Ebert, M. A., Rowshanfarzad, P., Francis, R. J. and Schultz, C. J. (2024). Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT. International Journal of Cardiovascular Imaging, 40 (9), 1847-1861. doi: 10.1007/s10554-024-03171-2

Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT

2024

Journal Article

The Australian Traumatic Brain Injury Initiative: systematic review of clinical factors associated with outcomes in people with moderate-severe traumatic brain injury

McKimmie, Ancelin, Keeves, Jemma, Gadowski, Adelle, Bagg, Matthew K., Antonic-Baker, Ana, Hicks, Amelia J., Hill, Regina, Clarke, Nyssa, Holland, Andrew, Veitch, Bill, Fatovich, Daniel, Reeder, Sandy, Romero, Lorena, Ponsford, Jennie L., Lannin, Natasha A., O’Brien, Terence J., Cooper, D. Jamie, Rushworth, Nick, Fitzgerald, Melinda, Gabbe, Belinda J., Cameron, Peter A., Alexander, Tara, Anderson, Vicki, Armstrong, Elizabeth, Babl, Franz E., Balogh, Zsolt J., Barlow, Karen M. (AUS-TBI Investigators member), Bellapart, Judith, Bidargaddi, Niranjan ... Zeeman, Heidi (2024). The Australian Traumatic Brain Injury Initiative: systematic review of clinical factors associated with outcomes in people with moderate-severe traumatic brain injury. Neurotrauma Reports, 5 (1), 640-659. doi: 10.1089/neur.2023.0111

The Australian Traumatic Brain Injury Initiative: systematic review of clinical factors associated with outcomes in people with moderate-severe traumatic brain injury

2024

Journal Article

Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer

Buteau, James P., Moon, Daniel, Fahey, Michael T., Roberts, Matthew J., Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, De Abreu Lourenco, Richard, Dhillon, Haryana M., Kasivisvanathan, Veeru, Francis, Roslyn J., Stricker, Phillip, Agrawal, Shihka, O'Brien, Jonathan, McVey, Aoife, Sharma, Gaurav, Levy, Sidney, Ayati, Narjess, Nguyen, Andrew, Lee, Su-Faye, Pattison, David A., Sivaratnam, Dinesh, Frydenberg, Mark, Du, Yang, Titus, Jehan, Lee, Sze-Ting, Ischia, Joseph, Jack, Greg ... Emmett, Louise (2024). Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer. European Urology Oncology, 7 (3), 544-552. doi: 10.1016/j.euo.2023.11.008

Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer

2024

Journal Article

An automated radiosynthesis of [68Ga]Ga-FAPI-46 for routine clinical use

Morandeau, Laurence, Ioppolo, Joseph A., Alvarez de Eulate, Eva, Mohamed, Shifaza, Cullen, Danica, Asad, Ali H., Francis, Roslyn J. and Atkinson, Janette (2024). An automated radiosynthesis of [68Ga]Ga-FAPI-46 for routine clinical use. Journal of Visualized Experiments, 2024 (207) e66708. doi: 10.3791/66708

An automated radiosynthesis of [68Ga]Ga-FAPI-46 for routine clinical use

2024

Journal Article

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Gedye, Craig, Rutherford, Natalie K., Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P., Voskoboynik, Mark, Redfern, Andrew D., Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Davis, Ian D. (2024). [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. The Lancet Oncology, 25 (5), 563-571. doi: 10.1016/s1470-2045(24)00135-9

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

2024

Journal Article

Plasma lipoprotein(a) is associated with calcification activity of the thoracic aorta and aortic valve in statin naïve individuals with diabetes mellitus

Bellinge, Jamie W., Chan, Dick C., Pang, Jing, Francis, Roslyn J., Page, Michael M., Watts, Gerald F. and Schultz, Carl J. (2024). Plasma lipoprotein(a) is associated with calcification activity of the thoracic aorta and aortic valve in statin naïve individuals with diabetes mellitus. European Journal of Clinical Investigation, 54 (5) e14167. doi: 10.1111/eci.14167

Plasma lipoprotein(a) is associated with calcification activity of the thoracic aorta and aortic valve in statin naïve individuals with diabetes mellitus

2024

Conference Publication

The feasibility of peri-coronary fat attenuation analysis on non-contrast cardiac CT and association with microcalcification activity

Bellinge, Brynn, Smith, B., Bellinge, J., Francis, R. and Schultz, C. (2024). The feasibility of peri-coronary fat attenuation analysis on non-contrast cardiac CT and association with microcalcification activity. RACP Congress 2024, Shaping Healthcare, Sydney, NSW, Australia, 16-17 May 2024. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/imj.16_16398

The feasibility of peri-coronary fat attenuation analysis on non-contrast cardiac CT and association with microcalcification activity

2024

Journal Article

The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy – a prospective cohort study

May, Isaac J., Nowak, Anna K., Francis, Roslyn J., Ebert, Martin A. and Dhaliwal, Satvinder S. (2024). The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy – a prospective cohort study. Journal of Medical Imaging and Radiation Oncology, 68 (1), 57-66. doi: 10.1111/1754-9485.13592

The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy – a prospective cohort study

2024

Journal Article

The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of pre-existing health conditions for people with moderate-severe traumatic brain injury

Antonic-Baker, Ana, Auvrez, Clarissa, Tao, Gerard, Bagg, Matthew K., Gadowski, Adelle, McKimmie, Ancelin, Hicks, Amelia J., Hill, Regina, Romero, Lorena, Ponsford, Jennie L., Lannin, Natasha A., Gabbe, Belinda J., Cameron, Peter A., Cooper, D. Jamie, Rushworth, Nick, Fitzgerald, Melinda, O'Brien, Terence J., Alexander, Tara, Anderson, Vicki, Armstrong, Elizabeth, Babl, Franz E., Balogh, Zsolt J., Barlow, Karen M. (AUS-TBI Initiative Investigators group member), Bellapart, Judith, Bidargaddi, Niranjan, Bosio, Erika, Bragge, Peter, Bynevelt, Michael, Caeyenberghs, Karen ... Zeeman, Heidi (2024). The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of pre-existing health conditions for people with moderate-severe traumatic brain injury. Journal of Neurotrauma. doi: 10.1089/neu.2023.0462

The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of pre-existing health conditions for people with moderate-severe traumatic brain injury

2024

Journal Article

The impact of fluorine-18-fluoroethyltyrosine positron emission tomography scan timing on radiotherapy planning in newly diagnosed patients with glioblastoma

Ryan, John, Hardcastle, Nicholas, Francis, Roslyn, Ferjančič, Peter, Ng, Sweet Ping, Koh, Eng-Siew, Geso, Moshi, Kelly, Jennifer and Ebert, Martin A. (2024). The impact of fluorine-18-fluoroethyltyrosine positron emission tomography scan timing on radiotherapy planning in newly diagnosed patients with glioblastoma. Physics and Imaging in Radiation Oncology, 29 100536, 100536. doi: 10.1016/j.phro.2024.100536

The impact of fluorine-18-fluoroethyltyrosine positron emission tomography scan timing on radiotherapy planning in newly diagnosed patients with glioblastoma

2024

Journal Article

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R., Williams, Scott G. ... Yip, Sonia (2024). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. The Lancet Oncology, 25 (1), 99-107. doi: 10.1016/s1470-2045(23)00529-6

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

2024

Journal Article

The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of demographic, injury event, and social characteristics on outcomes for people with moderate-severe traumatic brain injury

Gabbe, Belinda J., Keeves, Jemma, Mckimmie, Ancelin, Gadowski, Adelle M., Holland, Andrew J., Semple, Bridgette D., Young, Jesse T., Crowe, Louise, Ownsworth, Tamara, Bagg, Matthew K., Antonic-Baker, Ana, Hicks, Amelia J., Hill, Regina, Curtis, Kate, Romero, Lorena, Ponsford, Jennie L., Lannin, Natasha A., O'brien, Terence J., Cameron, Peter A., Cooper, Jamie, Rushworth, Nick, Fitzgerald, Melinda, Alexander, Tara, Anderson, Vicki, Armstrong, Elizabeth, Babl, Franz E., Balogh, Zsolt J., Barlow, Karen M. (AUS-TBI Initiative Investigators member), Bellapart, Judith ... Honeybul, Stephen (2024). The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of demographic, injury event, and social characteristics on outcomes for people with moderate-severe traumatic brain injury. Journal of Neurotrauma. doi: 10.1089/neu.2023.0461

The Australian traumatic brain injury initiative: systematic review and consensus process to determine the predictive value of demographic, injury event, and social characteristics on outcomes for people with moderate-severe traumatic brain injury

2023

Journal Article

Quantitative [68Ga]Ga-PSMA-11 PET biomarkers for the analysis of lesion-level progression in biochemically recurrent prostate cancer: a multicentre study

Kendrick, Jake, Francis, Roslyn J., Hassan, Ghulam Mubashar, Rowshanfarzad, Pejman, Ong, Jeremy S. L., Barry, Nathaniel, Rusanov, Branimir and Ebert, Martin A. (2023). Quantitative [68Ga]Ga-PSMA-11 PET biomarkers for the analysis of lesion-level progression in biochemically recurrent prostate cancer: a multicentre study. Scientific Reports, 13 (1) 17673, 17673. doi: 10.1038/s41598-023-45106-2

Quantitative [68Ga]Ga-PSMA-11 PET biomarkers for the analysis of lesion-level progression in biochemically recurrent prostate cancer: a multicentre study

Funding

Current funding

  • 2020 - 2026
    A new radio-imaging agent to guide targeted therapy for epithelial ovarian cancer
    NHMRC MRFF EPCDR - Ovarian Cancer Research
    Open grant

Supervision

Availability

Professor Roslyn Francis is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

For media enquiries about Professor Roslyn Francis's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au